Psychedelic Research Recap: January 2026

January 2026 was a compact month for psychedelic research, with seven papers spanning clinical studies, human mechanisms, a case report, and broader reviews. The clinical papers stayed close to care: esketamine for adolescents at immediate suicide risk, psilocybin-assisted therapy for binge eating disorder, and a group retreat model for people with metastatic cancer.

Clinical Studies Near Care

Three patient studies tested whether psychedelic or psychedelic-adjacent treatments can be delivered safely in settings that resemble future care models.

A double-blind Phase IIb study tested intranasal esketamine for adolescents with major depressive disorder and imminent suicide risk. Esketamine added to comprehensive standard care reduced depressive symptoms more than midazolam 24 hours after the first dose when the 56 mg and 84 mg dose groups were pooled. Suicidality improved in all groups but did not clearly separate between arms. Side effects such as dizziness, nausea, dissociation, and short-lived blood pressure increases were common but generally transient.

A small open-label pilot study tested psilocybin-assisted therapy for binge eating disorder. Five adults received a single 25 mg dose of psilocybin with Acceptance and Commitment Therapy-based psychotherapy. The intervention was feasible and well tolerated, with no serious adverse events. Participants reported fewer binge eating episodes and improvements in depression, anxiety, and psychological flexibility over 14 weeks, but the sample size and open-label design make this an early signal rather than a firm efficacy finding.

A Phase 1/2 open-label study tested group retreat psilocybin therapy for people with metastatic cancer and symptoms of anxiety or depression. Across 52 participants, the retreat format was delivered without unattended distress episodes, and no serious adverse events were attributed to psilocybin. Anxiety and depression scores improved over 28 days, demoralisation fell, and quality of life increased. The study mainly shows that a carefully designed group model can be run safely enough to justify stronger controlled studies.

Human Effects And Case Evidence

Two smaller human papers looked at lived and measured effects: one in healthy volunteers, and one in a single patient.

In healthy volunteers, psilocybin changed both objective and subjective time perception. On a temporal bisection task, participants judged intervals as slower and less precise under psilocybin than under placebo, especially for intervals longer than two seconds. Their task performance matched their own reports that time was passing more slowly, suggesting that psilocybin can disrupt temporal judgement in ways that are both measurable and felt.

A single-patient case report described low-dose ibogaine hydrochloride in a woman with Parkinson's disease over 80 days. The patient showed improvements in motor symptoms, quality of life, fatigue, and depression, while sleep worsened and no adverse events were recorded. The report is descriptive and cannot establish efficacy, but it gives a structured clinical account in an area that has mostly been discussed through anecdote.

Reviews And Implementation

The two broader papers looked at the evidence base from different angles: clinical effects in treatment-resistant depression, and what European systems may need before psychedelic therapies reach routine care.

A systematic review of 15 studies on psychedelics for treatment-resistant depression found a pattern of rapid and clinically meaningful symptom reduction across different compounds. The review included ten randomised double-blind controlled trials and five open-label trials. It presents psychedelics as possible alternative or adjunctive treatments, while also making clear that study designs, comparators, and follow-up periods still vary considerably.

A review on implementation in European healthcare systems argues that regulatory approval will not be enough by itself. The authors highlight health technology assessment, active-comparator evidence, longer follow-up, and reimbursement decisions as central issues, using esketamine as one example of how access can depend on evidence beyond placebo-controlled trials. The practical point is that psychedelic therapy development needs to be planned with regulators, payers, and delivery teams in mind.